$8.56
0.81% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US0887861088
Symbol
BCYC
Sector
Industry

Bicycle Therapeutics Plc Stock price

$8.51
+1.00 13.32% 1M
-11.85 58.20% 6M
-5.49 39.21% YTD
-13.20 60.80% 1Y
-8.79 50.81% 3Y
-6.49 43.27% 5Y
-5.49 39.21% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.12 1.39%
ISIN
US0887861088
Symbol
BCYC
Sector
Industry

Key metrics

Market capitalization $588.91m
Enterprise Value $-194.94m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.07
EV/Sales (TTM) EV/Sales -7.57
P/S ratio (TTM) P/S ratio 22.86
P/B ratio (TTM) P/B ratio 0.80
Revenue growth (TTM) Revenue growth -38.14%
Revenue (TTM) Revenue $25.76m
EBIT (operating result TTM) EBIT $-284.91m
Free Cash Flow (TTM) Free Cash Flow $-182.50m
Cash position $792.97m
EPS (TTM) EPS $-3.14
P/E forward negative
P/S forward 15.81
EV/Sales forward negative
Short interest 8.44%
Show more

Is Bicycle Therapeutics Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Bicycle Therapeutics Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Bicycle Therapeutics Plc forecast:

11x Buy
79%
3x Hold
21%

Analyst Opinions

14 Analysts have issued a Bicycle Therapeutics Plc forecast:

Buy
79%
Hold
21%

Financial data from Bicycle Therapeutics Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
26 26
38% 38%
100%
- Direct Costs 7.16 7.16
8% 8%
28%
19 19
47% 47%
72%
- Selling and Administrative Expenses 62 62
26% 26%
239%
- Research and Development Expense 235 235
22% 22%
911%
-278 -278
35% 35%
-1,078%
- Depreciation and Amortization 7.16 7.16
8% 8%
28%
EBIT (Operating Income) EBIT -285 -285
34% 34%
-1,106%
Net Profit -204 -204
21% 21%
-790%

In millions USD.

Don't miss a Thing! We will send you all news about Bicycle Therapeutics Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bicycle Therapeutics Plc Stock News

Neutral
Business Wire
15 days ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on May 1, 2025, the Compensation Committee of the company's Board of Directors granted to 13 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 79,500 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Pla...
Neutral
Business Wire
20 days ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2025. “In the first quarter, we continued to advance our busin...
Neutral
Business Wire
22 days ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced the presentation of additional human imaging data that validate the potential of MT1-MMP, a tumor antigen overexpressed in many cancers, as a novel t...
More Bicycle Therapeutics Plc News

Company Profile

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Kevin Lee
Employees 305
Founded 2009
Website bicycletherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today